Combination of Micropulse Laser With or Without Photodynamic Therapy for Chronic Central Serous Chorioretinopathy

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-70
SponsorBeijing Hospital

About this trial

In this study, patients with chronic central serous chorioretinopathy who were treated by micropulse laser alone or micropulse laser combined with photodynamic therapy without drugs are retrospectively included. The visual acuity changes, subretinal fluid absorption and choroidal characteristics of the two groups are compared 1 to 6 months after treatment. We will also analyze baseline characteristics that influence post-treatment outcomes to identify potential predictors of poor treatment outcomes.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age >18 years old.

The patient diagnosed with chronic central serous chorioretinopathy with a history of more than 6 months. The diagnostic criteria for chronic CSC were as follows: FFA examination showed leakage of strong fluorescent spots with the extension of angiography time, and late fluorescence accumulation, accompanied by decreased central vision, darkening of vision, and deformable microopia. Fundus examination showed superficial detachment of retinal neuroepithelium in macula.

Patients received single micropulse laser therapy or micropulse laser combined with drug-free photodynamic therapy, and had not received other laser or surgical treatment in the six months prior to treatment.

Patients had follow-up data before and after treatment for 1 month and at least 6 months.

Disqualifiers

Patients with other fundus diseases or refractive interstitial opacity.

During treatment, other treatments other than micropulse laser or drug-free photodynamic therapy were received.

Various reasons led to incomplete patient data.

Trial population

The patient diagnosed with chronic central serous chorioretinopathy with a history of more than 6 months, who received single micropulse laser therapy or micropulse laser combined with drug-free photodynamic therapy.

Trial design

Design model

Case-only

Time perspective

Retrospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

BCVA

Best-corrected visual acuity using logMAR

Time frame
1 month and 6 months
2

CRT

Central retinal thickness on OCT

Time frame
1 month and 6 months

Secondary outcomes

1

SFCT

subfoveal choroidal thickness on OCTA

Time frame
1 month and 6 months

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: